FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3025342605> ?p ?o ?g. }

• W3025342605 endingPage "8" @default.
• W3025342605 startingPage "1" @default.
• W3025342605 abstract "A retrospective evaluation of the results of treatment of myopic choroidal neovascularization (mCNV) with intravitreal injections of ranibizumab in a pro re nata (PRN) regimen in three groups of patients distributed according to axial length.The paper presents a retrospective multicenter study carried out with the cooperation of several Departments of Ophthalmology in the Czech Republic. The study included 60 eyes of 60 patients suffering from mCNV, divided according to axial length into three groups. The first group consisted of 20 patients with an axial length of the eyes shorter than 28 mm (Group 1), the second group included 27 patients with axial lengths ranging from 28 mm to 29.81 mm (Group 2), and 13 patients had axial lengths longer than 30 mm (Group 3). All patients were first administered 3 initial intravitreal ranibizumab injections at monthly intervals (loading phase), and other injections were administered according to a PRN treatment regimen. Patients were evaluated before treatment and then at intervals of 3, 6, 9, and 12 months. The effect of ranibizumab treatment on the functional and morphological parameters of the affected eye was evaluated.The average baseline BCVA ± SD in Group 1 was 52.6 ± 12.5 letters of ETDRS optotypes, and at the end of the one-year follow-up, it was 63.3 ± 11.8 letters. The average baseline of CRT ± SD in this group was 377.4 ± 80.0 μm, and in the 12th month, it was 311.1 ± 63.7 μm. The average baseline BCVA ± SD in Group 2 was 50.2 ± 9.0 ETDRS letters, and at the end of the follow-up, it was 60 ± 12.4 letters. The average baseline of CRT ± SD in Group 2 was 391.2 ± 85.2 μm, and in the 12th month, it was 323.9 ± 91.2 μm. In Group 3, the average baseline of BCVA was 48.5 ± 14.5 ETDRS letters, and at the end of the one-year follow-up, it was 55.7 ± 16.1 letters. The average baseline CRT ± SD for Group 3 was 342.1 ± 94.9 μm, and after 12 months, it was 287.8 ± 88.4 μm. An improvement of BCVA by ≥15 letters of ETDRS optotypes was achieved by 3 patients of 20 (15%) in Group 1, by 5 patients of 27 (18.5%) in Group 2, and by 3 patients of 13 (23.1%) in Group 3. All these changes were statistically significant in comparison with the input values (p < 0.05).Ranibizumab treatment in patients with mCNV in our study resulted in statistically significant improvement in BCVA and a decrease in CRT in all groups of patients. Our results from a routine clinical practice correspond with the results of large clinical studies; we confirm a particularly good effect of treatment in patients with axial lengths of the eye smaller than 28 mm." @default.
• W3025342605 created "2020-05-21" @default.
• W3025342605 creator A5011755152 @default.
• W3025342605 creator A5024822935 @default.
• W3025342605 creator A5042913513 @default.
• W3025342605 creator A5049892485 @default.
• W3025342605 creator A5050611053 @default.
• W3025342605 creator A5065149835 @default.
• W3025342605 creator A5090250081 @default.
• W3025342605 date "2020-05-13" @default.
• W3025342605 modified "2023-10-14" @default.
• W3025342605 title "Results of Ranibizumab Treatment of the Myopic Choroidal Neovascular Membrane according to the Axial Length of the Eye" @default.
• W3025342605 cites W141996282 @default.
• W3025342605 cites W2001862779 @default.
• W3025342605 cites W2003759790 @default.
• W3025342605 cites W2004361001 @default.
• W3025342605 cites W2005450884 @default.
• W3025342605 cites W2045532670 @default.
• W3025342605 cites W2046924409 @default.
• W3025342605 cites W2047083844 @default.
• W3025342605 cites W2053445386 @default.
• W3025342605 cites W2060609110 @default.
• W3025342605 cites W2070142790 @default.
• W3025342605 cites W2082606620 @default.
• W3025342605 cites W2085039880 @default.
• W3025342605 cites W2087703104 @default.
• W3025342605 cites W2108341916 @default.
• W3025342605 cites W2161156567 @default.
• W3025342605 cites W2315997705 @default.
• W3025342605 cites W2417725951 @default.
• W3025342605 cites W4238767607 @default.
• W3025342605 cites W4252511080 @default.
• W3025342605 cites W43396993 @default.
• W3025342605 cites W54175922 @default.
• W3025342605 doi "https://doi.org/10.1155/2020/3076596" @default.
• W3025342605 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7243022" @default.
• W3025342605 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32454987" @default.
• W3025342605 hasPublicationYear "2020" @default.
• W3025342605 type Work @default.
• W3025342605 sameAs 3025342605 @default.
• W3025342605 citedByCount "4" @default.
• W3025342605 countsByYear W30253426052022 @default.
• W3025342605 countsByYear W30253426052023 @default.
• W3025342605 crossrefType "journal-article" @default.
• W3025342605 hasAuthorship W3025342605A5011755152 @default.
• W3025342605 hasAuthorship W3025342605A5024822935 @default.
• W3025342605 hasAuthorship W3025342605A5042913513 @default.
• W3025342605 hasAuthorship W3025342605A5049892485 @default.
• W3025342605 hasAuthorship W3025342605A5050611053 @default.
• W3025342605 hasAuthorship W3025342605A5065149835 @default.
• W3025342605 hasAuthorship W3025342605A5090250081 @default.
• W3025342605 hasBestOaLocation W30253426051 @default.
• W3025342605 hasConcept C118487528 @default.
• W3025342605 hasConcept C119767625 @default.
• W3025342605 hasConcept C141071460 @default.
• W3025342605 hasConcept C167135981 @default.
• W3025342605 hasConcept C2776694085 @default.
• W3025342605 hasConcept C2777802072 @default.
• W3025342605 hasConcept C2778257484 @default.
• W3025342605 hasConcept C2780699112 @default.
• W3025342605 hasConcept C2781100027 @default.
• W3025342605 hasConcept C2781359195 @default.
• W3025342605 hasConcept C2781413609 @default.
• W3025342605 hasConcept C71924100 @default.
• W3025342605 hasConceptScore W3025342605C118487528 @default.
• W3025342605 hasConceptScore W3025342605C119767625 @default.
• W3025342605 hasConceptScore W3025342605C141071460 @default.
• W3025342605 hasConceptScore W3025342605C167135981 @default.
• W3025342605 hasConceptScore W3025342605C2776694085 @default.
• W3025342605 hasConceptScore W3025342605C2777802072 @default.
• W3025342605 hasConceptScore W3025342605C2778257484 @default.
• W3025342605 hasConceptScore W3025342605C2780699112 @default.
• W3025342605 hasConceptScore W3025342605C2781100027 @default.
• W3025342605 hasConceptScore W3025342605C2781359195 @default.
• W3025342605 hasConceptScore W3025342605C2781413609 @default.
• W3025342605 hasConceptScore W3025342605C71924100 @default.
• W3025342605 hasLocation W30253426051 @default.
• W3025342605 hasLocation W30253426052 @default.
• W3025342605 hasLocation W30253426053 @default.
• W3025342605 hasLocation W30253426054 @default.
• W3025342605 hasLocation W30253426055 @default.
• W3025342605 hasOpenAccess W3025342605 @default.
• W3025342605 hasPrimaryLocation W30253426051 @default.
• W3025342605 hasRelatedWork W2025941674 @default.
• W3025342605 hasRelatedWork W2089092235 @default.
• W3025342605 hasRelatedWork W2121621777 @default.
• W3025342605 hasRelatedWork W2558708349 @default.
• W3025342605 hasRelatedWork W2990113520 @default.
• W3025342605 hasRelatedWork W3008057863 @default.
• W3025342605 hasRelatedWork W3015481187 @default.
• W3025342605 hasRelatedWork W4281630725 @default.
• W3025342605 hasRelatedWork W4381328474 @default.
• W3025342605 hasRelatedWork W4386589961 @default.
• W3025342605 hasVolume "2020" @default.
• W3025342605 isParatext "false" @default.
• W3025342605 isRetracted "false" @default.
• W3025342605 magId "3025342605" @default.
• W3025342605 workType "article" @default.